Omnio is developing recombinant plasminogen for treatment of chronic wounds. Specialized recombinant cells are made to produce large amounts of the protein plasminogen in big bioreactors. The protein is then purified and concentrated to be used for clinical studies. Plasminogen is a protein normally produced in the body and our drug product is expected to produce little to no adverse effects.
The drug candidate is classified as a biological medical product the same class as antibodies.